Critic of Drug Industry and COVID-19 Measures Appointed to Lead FDA Vaccine Program

WASHINGTON (AP) — Dr. Vinay Prasad, a well-known critic of the pharmaceutical industry and COVID-19 policies, has been appointed to lead the U.S. Food and Drug Administration’s (FDA) program for vaccines and biotech drugs.

FDA Commissioner Dr. Marty Makary made the announcement on Tuesday, acknowledging Prasad’s “long and distinguished history in medicine.” This move marks a significant shift in leadership, as Prasad is stepping into a role traditionally held by a career scientist at the FDA, raising questions about how this might impact vaccine approval processes.

Prasad, who has long been vocal in his opposition to various pharmaceutical industry practices, is the latest figure from the medical and political fringes to join the federal government under President Donald Trump. His appointment, however, has sparked concerns over whether new therapies will face heightened scrutiny, potentially slowing down approval processes for vaccines and other critical treatments.

Prasad takes over from Dr. Peter Marks, the FDA’s previous vaccine chief, who resigned in March following disagreements with Health Secretary Robert F. Kennedy Jr. over vaccine safety issues. In a social media post, Prasad sharply criticized Marks, calling him “a bobblehead doll that just stamps approval.”

In interviews, Prasad has made his views on the FDA clear, suggesting that the agency’s current form may not be beneficial. Last year, during a podcast with former Republican presidential candidate Vivek Ramaswamy, Prasad boldly stated that Americans might be “better off” without the FDA as it stands.

Prasad, a professor at the University of California San Francisco, has a medical background in cancer and blood disorders. He first gained recognition in academic circles for scrutinizing cancer therapies, showing that many fast-tracked cancer drugs approved by the FDA had never been proven to improve patient outcomes. These drugs were often approved based on measures like tumor shrinkage, which is thought to be a predictive sign of long-term survival but does not guarantee actual improvements in patients’ lives.

The FDA has consistently defended this approach as a way to expedite the approval of medications for patients with serious or terminal conditions.

During the COVID-19 pandemic, Prasad gained wider attention for his criticisms of vaccine mandates, mask mandates, lockdowns, and the accelerated approval of booster shots from Pfizer and Moderna. His stance echoed that of other Trump appointees like Makary and National Institutes of Health (NIH) Director Jay Bhattacharya.

In 2022, Prasad and Makary co-authored a paper criticizing the recommendation for booster shots in teens and young adults, particularly males, due to concerns about the risk of myocarditis (a rare heart condition). The paper argued that mandating boosters for this group could cause more harm than good, though it was met with resistance from experts who noted that none of the authors were specialists in infectious diseases or vaccine reactions.

Angela Rasmussen, a virus expert at the University of Saskatchewan, expressed concern about Prasad’s appointment, predicting that it could harm vaccine access in the U.S. and hinder transparency in vaccine approvals. Rasmussen warned that Prasad’s leadership could lead to fewer approvals and a decrease in the public’s access to vaccines.

In recent years, Prasad has become a prominent voice in podcasts aligned with the “Make America Healthy Again” movement, which often criticizes the FDA for being too closely tied to the pharmaceutical industry.

Prasad’s appointment is sure to cause unease among drug and vaccine manufacturers, as they rely on the predictability and stability of the FDA’s standards to guide their lengthy and costly drug development processes.

Prasad’s leadership at the FDA will likely be a point of contention in the coming months, as debates over vaccine safety and pharmaceutical industry influence continue to shape public health discussions.